X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Indian markets open in deep red 
(Fri, 4 Sep 09:30 am) 
 
The major Asian stock markets have opened the day in red. The stock market in Japan, Singapore and China are down by 1.9%, 1.2% and 0.4% respectively, leading the pack of losers. Even, the stock market in the US ended their previous session in red. While, the major stock indices in the Europe ended their previous session on an encouraging note. The rupee is trading at 66.26 per US dollar.

Indian stock markets have too opened the day on quite a disappointing note amidst weak global cues. BSE-Sensex is trading down by 450 points (down 1.8%) and NSE-Nifty is trading down by 140 points (down 1.7%). Both S&P BSE Midcap and S&P BSE Smallcap is trading down by 1.8% and 2.3% respectively. Sectoral indices have too opened weak with stocks from metals and banking and automobile sector witnessing maximum selling pressure.

The stock of Amtek is under fire, since some time. The stock has lost, around 83% in last one month. According to a financial daily, the prime reason for the sharp plunge in the stock price is weak quarterly results. The sales from major geographies have been declining. Further, the company has debt of more than Rs 150 bn in its books. This has prompted fears, if the company will be able to meet its financial obligations and thus, leading to a sharp sell-off. The stock has opened down by 12% today.

Major stocks in the pharmaceutical sector have opened their day in red. As per an articles in Business Standard, Cipla is in talks to acquire 'Hetero Drugs' US business. Reportedly, the deal is expected to be valued at $500-550m. This transaction will help the company; to expand its generic drug portfolio. US business currently accounts for roughly 8% of Cipla's total revenue. The company is keen to expand its market share in this region. If the deal fructifies; will be the second largest acquisition by an Indian company in two months in US. Stock of Cipla is trading up by 1.9%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "Indian markets open in deep red". Click here!

  
 

S&P BSE HEALTHCARE


Jun 23, 2017 02:17 PM

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS